Skip to main content
Premium Trial:

Request an Annual Quote

John Sowatsky, David Bentley, Mark Whitman, Michael Terry, and Ecogenomics

Premium

People in the News

NanoString Technologies has named John Sowatsky as vice president of product development, the Seattle-based firm said last week.

Sowatsky most recently served as vice president of system business unit at Affymetrix, where he held various informatics-related management positions since he joined the firm in 1995, including manager and director of software development and vice president of informatics and instrumentation.

Prior to his time at Affy, Sowatsky held positions at Abbott Laboratories and at LifeScan, a Johnson & Johnson company.



David Bentley will join Solexa as chief scientist on Sept. 5, the company said last week. He comes to Solexa from the Wellcome Trust Sanger Institute, where he was a founding member of the management team, holding the position of head of human genetics. At Solexa, Bentley will spearhead the company's DNA sequencing applications development and projects. He has been on Solexa's scientific advisory board since 1998 and is a co-inventor of aspects of the company's technology. Bentley holds a DPhil from the University of Oxford and an MA in biochemistry from the University of Cambridge.


Mark Whitman has joined the scientific advisory board of CombiMatrix Molecular Diagnostics, the company said last week. He will also be a company consultant in the area of melanoma diagnosis and management. Whitman is the administrative director of surgical services and the director of the melanoma center at Mountainside Hospital in Montclair, New Jersey. He holds a medical degree from Pennsylvania State University School of Medicine and a BA in chemistry from Haverford College.


Michael Terry, executive vice president of sales and marketing at Sequenom, has left the company on July 25, the company said in an SEC filing. He will remain available to "provide reasonable consulting services," Sequenom said.

 

New Product Watch

Ecogenomics last week launched DNA micorarrays for evaluating the adverse effects of chemical substances including the EG Microarray Killifish 750 for killifish experiments, the EG Microarray Mouse 1200, and the EG Microarray 12chamber which Ecogenomics claims can provide gene expression analysis of 12 different samples per chip.

The Japanese firm said the arrays retail for ¥25,000 ($227), ¥27,500 and ¥30,000, respectively.

 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.